[HTML][HTML] The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms

R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle… - Leukemia, 2022 - nature.com
We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

TK Kim, EN Vandsemb, RS Herbst… - Nature Reviews Drug …, 2022 - nature.com
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

H Yamaguchi, JM Hsu, WH Yang… - Nature Reviews Clinical …, 2022 - nature.com
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Programmed death ligand 1 signals in cancer cells

AVR Kornepati, RK Vadlamudi, TJ Curiel - Nature Reviews Cancer, 2022 - nature.com
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

[HTML][HTML] Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

H Zhang, Z Dai, W Wu, Z Wang, N Zhang… - Journal of Experimental …, 2021 - Springer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

[HTML][HTML] Regulation of PD-L1 expression in the tumor microenvironment

M Yi, M Niu, L Xu, S Luo, K Wu - Journal of hematology & oncology, 2021 - Springer
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

K Chamoto, T Yaguchi, M Tajima, T Honjo - Nature Reviews …, 2023 - nature.com
PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

Genomic profiling for clinical decision making in lymphoid neoplasms

L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

[HTML][HTML] Regulation and function of the PD-L1 checkpoint

C Sun, R Mezzadra, TN Schumacher - Immunity, 2018 - cell.com
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …